Literature DB >> 9006414

The natural course of cerebral lesions in Sneddon syndrome.

A Tourbah1, J C Piette, M T Iba-Zizen, O Lyon-Caen, P Godeau, C Francès.   

Abstract

OBJECTIVES: To characterize the clinical, biological, and neuroradiological findings in Sneddon syndrome; to correlate magnetic resonance imaging abnormalities with disability, presence of hypertension and other vascular risk factors, presence of heart valvulopathy on echography, and titer of antiphospholipid antibodies; and to compare these findings in antiphospholipid-positive and antiphospholipid-negative patients.
DESIGN: Retrospective review of the records of 32 consecutive patients with livedo reticularis and neurological events, followed up in our institution between January 1991 and August 1995. PATIENTS: Twenty-six patients (20 women and 6 men) who had at least 1 cerebral ischemic arterial event associated with generalized and pathological livedo reticularis.
RESULTS: The age at the first cerebral ischemic event ranged from 22 to 58 years. Motor deficit was the most frequent sign (found in 73% of cases). Disability was found in 50%, systemic hypertension in 65%, heart valvulopathy in 61%, and antiphospholipid antibodies in 42% of cases. Patients were classified in 6 groups according to magnetic resonance imaging findings. No correlation was found between the presence of hypertension or other vascular risk factors, valvulopathy, antiphospholipids, and magnetic resonance imaging abnormalities. There was no significant difference between antiphospholipid-positive and antiphospholipid-negative patients except for the presence of antinuclear antibodies. There was a significant correlation between the extent of magnetic resonance imaging abnormalities and disability.
CONCLUSION: The severity of the disease seems to be correlated with magnetic resonance imaging aspects, but not to the presence of antiphospholipid antibodies. Magnetic resonance imaging may help to understand the natural course of the cerebral involvement of the disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9006414     DOI: 10.1001/archneur.1997.00550130037013

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  8 in total

Review 1.  Identification and management of difficult stroke and TIA syndromes.

Authors:  M M Brown
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-04       Impact factor: 10.154

Review 2.  Neuroimaging techniques in the diagnostic work-up of patients with the antiphospholipid syndrome.

Authors:  M Rovaris; C Pedroso; M Filippi
Journal:  Curr Rheumatol Rep       Date:  2001-08       Impact factor: 4.592

Review 3.  Intracerebral hemorrhage associated with Sneddon's syndrome: is ischemia-related angiogenesis the cause? Case report and review of the literature.

Authors:  F de A Aquino Gondim; R O Leacock; T A Subrammanian; S Cruz-Flores
Journal:  Neuroradiology       Date:  2003-05-16       Impact factor: 2.804

4.  Improvement of neurological symptoms and memory and emotional status in a case of seronegative Sneddon syndrome with cyclophosphamide.

Authors:  Peter M Hannon; Sheng-Han Kuo; Adriana M Strutt; Michele K York; Joseph S Kass
Journal:  Clin Neurol Neurosurg       Date:  2010-05-04       Impact factor: 1.876

Review 5.  The spectrum of differential diagnosis in neurological patients with livedo reticularis and livedo racemosa. A literature review.

Authors:  Markus Kraemer; Dieter Linden; Peter Berlit
Journal:  J Neurol       Date:  2005-08-26       Impact factor: 4.849

Review 6.  Sneddon's syndrome: a comprehensive review of the literature.

Authors:  Shengjun Wu; Ziqi Xu; Hui Liang
Journal:  Orphanet J Rare Dis       Date:  2014-12-31       Impact factor: 4.123

7.  Coexistence of scleromyxedema and Sneddon syndrome.

Authors:  Antonio Furci; Micol Del Giglio; Francesco Bellinato; Chiara Colato; Giampiero Girolomoni
Journal:  JAAD Case Rep       Date:  2021-03-20

8.  Sneddon Syndrome: A Case Report Exploring the Current Challenges Faced with Diagnosis and Management.

Authors:  Jonathan Cleaver; Mario Teo; Shelley Renowden; Keith Miller; Harsha Gunawardena; Philip Clatworthy
Journal:  Case Rep Neurol       Date:  2019-12-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.